John G Ullman & Associates Inc. Has $348,000 Stock Holdings in Roche Holding AG (OTCMKTS:RHHBY)

John G Ullman & Associates Inc. lessened its holdings in Roche Holding AG (OTCMKTS:RHHBY) by 39.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,600 shares of the company’s stock after selling 6,350 shares during the period. John G Ullman & Associates Inc.’s holdings in Roche were worth $348,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. First Horizon Advisors Inc. boosted its position in shares of Roche by 39.4% during the third quarter. First Horizon Advisors Inc. now owns 1,724 shares of the company’s stock worth $58,000 after purchasing an additional 487 shares in the last quarter. Operose Advisors LLC bought a new position in shares of Roche during the third quarter worth $59,000. Russell Investments Group Ltd. bought a new position in shares of Roche during the first quarter worth $103,000. Motco raised its holdings in shares of Roche by 612.7% during the third quarter. Motco now owns 4,426 shares of the company’s stock worth $151,000 after acquiring an additional 3,805 shares during the period. Finally, Paradigm Asset Management Co. LLC raised its holdings in shares of Roche by 18.4% during the third quarter. Paradigm Asset Management Co. LLC now owns 5,151 shares of the company’s stock worth $175,000 after acquiring an additional 800 shares during the period.

Analysts Set New Price Targets

RHHBY has been the topic of a number of research analyst reports. Morgan Stanley lowered shares of Roche from an “equal weight” rating to an “underweight” rating in a report on Tuesday, January 16th. Argus restated a “hold” rating on shares of Roche in a report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Roche presently has a consensus rating of “Hold” and a consensus price target of $40.00.

Roche Trading Up 1.2 %

Shares of RHHBY opened at $30.41 on Friday. The firm has a 50-day moving average of $32.07 and a 200-day moving average of $33.73. Roche Holding AG has a one year low of $29.95 and a one year high of $40.48. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.35 and a quick ratio of 1.04.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.